Back to top
more

OpGen (OPGN)

(Delayed Data from NSDQ)

$3.30 USD

3.30
25,475

0.00 (0.00%)

Updated May 28, 2024 04:00 PM ET

After-Market: $3.29 -0.01 (-0.30%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (94 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for OPGN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

OpGen, Inc. [OPGN]

Reports for Purchase

Showing records 21 - 40 ( 106 total )

Company: OpGen, Inc.

Industry: Medical Services

Record: 21

01/09/2023

Company Report

Pages: 2

New public offering to support funding needs

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party

Company: OpGen, Inc.

Industry: Medical Services

Record: 22

01/06/2023

Company Report

Pages: 4

Share consolidation to regain Nasdaq compliance

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party

Company: OpGen, Inc.

Industry: Medical Services

Record: 23

12/20/2022

Company Report

Pages: 6

Near-term adjustments with outlook unchanged

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 12.50

Research Provided by a Third Party

Company: OpGen, Inc.

Industry: Medical Services

Record: 24

12/14/2022

Company Report

Pages: 2

Test menu expansion opportunity with positive data

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party

Company: OpGen, Inc.

Industry: Medical Services

Record: 25

11/14/2022

Company Report

Pages: 2

Guidance revision triggered by softer Q322

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party

Company: OpGen, Inc.

Industry: Medical Services

Record: 26

10/28/2022

Company Report

Pages: 2

Broadening its commercial footprint in Q322

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party

Company: OpGen, Inc.

Industry: Medical Services

Record: 27

10/26/2022

Company Report

Pages: 2

Rapid detection collaboration with BioVersys

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party

Company: OpGen, Inc.

Industry: Medical Services

Record: 28

10/04/2022

Company Report

Pages: 2

Unyvero UTI panel approaching final readouts

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party

Company: OpGen, Inc.

Industry: Medical Services

Record: 29

10/03/2022

Company Report

Pages: 2

$3.38m raised through private placement

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party

Company: OpGen, Inc.

Industry: Medical Services

Record: 30

09/20/2022

Company Report

Pages: 2

Unyvero A30 RQ collaboration with FIND

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party

Company: OpGen, Inc.

Industry: Medical Services

Record: 31

08/26/2022

Company Report

Pages: 2

Addressing AMR with next-generation sequencing

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party

Company: OpGen, Inc.

Industry: Medical Services

Record: 32

08/12/2022

Company Report

Pages: 3

Re-acceleration with momentum in the back half

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party

Company: OpGen, Inc.

Industry: Medical Services

Record: 33

07/27/2022

Company Report

Pages: 2

Another collaboration agreement for Ares Genetics

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party

Company: OpGen, Inc.

Industry: Medical Services

Record: 34

07/11/2022

Company Report

Pages: 2

A catalyst-rich Q222

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party

Company: OpGen, Inc.

Industry: Medical Services

Record: 35

06/10/2022

Company Report

Pages: 6

Unyvero Commercial Distribution Expanded; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 12.50

Research Provided by a Third Party

Company: OpGen, Inc.

Industry: Medical Services

Record: 36

06/10/2022

Company Report

Pages: 2

Expanding presence in the Middle East

Provider: Edison Investment Research Limited

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: OpGen, Inc.

Industry: Medical Services

Record: 37

05/27/2022

Company Report

Pages: 6

Unyvero HPN Panel Clinical Study Data Published; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 12.50

Research Provided by a Third Party

Company: OpGen, Inc.

Industry: Medical Services

Record: 38

05/27/2022

Company Report

Pages: 2

Clinical peer-review supports the HPN panel Pharma and biotech

Provider: Edison Investment Research Limited

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: OpGen, Inc.

Industry: Medical Services

Record: 39

05/16/2022

Company Report

Pages: 5

US momentum offset by one-time items

Provider: Edison Investment Research Limited

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: OpGen, Inc.

Industry: Medical Services

Record: 40

05/13/2022

Company Report

Pages: 6

1Q22 Financial Results Reported; Reiterate Buy; Modulating PT to $3

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 12.50

Research Provided by a Third Party